Review





Similar Products

components  (MedChemExpress)
96
MedChemExpress components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Components, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/components/product/MedChemExpress
Average 96 stars, based on 1 article reviews
components - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
dlin mc3 dma  (Organix Inc)
86
Organix Inc dlin mc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Mc3 Dma, supplied by Organix Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin mc3 dma/product/Organix Inc
Average 86 stars, based on 1 article reviews
dlin mc3 dma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
dlin mc3 dma  (Alnylam Inc)
86
Alnylam Inc dlin mc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Mc3 Dma, supplied by Alnylam Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin mc3 dma/product/Alnylam Inc
Average 86 stars, based on 1 article reviews
dlin mc3 dma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
611a dynamic muscle analysis dma software  (Aurora Scientific)
86
Aurora Scientific 611a dynamic muscle analysis dma software
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
611a Dynamic Muscle Analysis Dma Software, supplied by Aurora Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/611a dynamic muscle analysis dma software/product/Aurora Scientific
Average 86 stars, based on 1 article reviews
611a dynamic muscle analysis dma software - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
dynamic mechanical analysis dma  (Hitachi Ltd)
99
Hitachi Ltd dynamic mechanical analysis dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dynamic Mechanical Analysis Dma, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dynamic mechanical analysis dma/product/Hitachi Ltd
Average 99 stars, based on 1 article reviews
dynamic mechanical analysis dma - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
front curve plastic mold dma n  (Ashland Inc)
86
Ashland Inc front curve plastic mold dma n
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Front Curve Plastic Mold Dma N, supplied by Ashland Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/front curve plastic mold dma n/product/Ashland Inc
Average 86 stars, based on 1 article reviews
front curve plastic mold dma n - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
6z 9 z 28 z 31 z heptatriaconta 6 9 28 31 tetraen 19 yl 4  (Croda International Plc)
95
Croda International Plc 6z 9 z 28 z 31 z heptatriaconta 6 9 28 31 tetraen 19 yl 4
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
6z 9 Z 28 Z 31 Z Heptatriaconta 6 9 28 31 Tetraen 19 Yl 4, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/6z 9 z 28 z 31 z heptatriaconta 6 9 28 31 tetraen 19 yl 4/product/Croda International Plc
Average 95 stars, based on 1 article reviews
6z 9 z 28 z 31 z heptatriaconta 6 9 28 31 tetraen 19 yl 4 - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
ionizable lipid d lin mc3 dma  (Sirna Therapeutics)
86
Sirna Therapeutics ionizable lipid d lin mc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Ionizable Lipid D Lin Mc3 Dma, supplied by Sirna Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ionizable lipid d lin mc3 dma/product/Sirna Therapeutics
Average 86 stars, based on 1 article reviews
ionizable lipid d lin mc3 dma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
dlin dma mc3  (MedChemExpress)
93
MedChemExpress dlin dma mc3
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Dma Mc3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin dma mc3/product/MedChemExpress
Average 93 stars, based on 1 article reviews
dlin dma mc3 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
benchmark d lin mc3 dma lipid  (MedChemExpress)
96
MedChemExpress benchmark d lin mc3 dma lipid
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Benchmark D Lin Mc3 Dma Lipid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/benchmark d lin mc3 dma lipid/product/MedChemExpress
Average 96 stars, based on 1 article reviews
benchmark d lin mc3 dma lipid - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Journal: bioRxiv

Article Title: Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

doi: 10.64898/2026.04.26.720919

Figure Lengend Snippet: A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Article Snippet: The following components were purchased from MedChemExpress; DLin-MC3-DMA (HY-112251), DOTAP (HY-112754A), 306-O12B (HY-W590532), DMG-PEG 2000 (HY-112764), DOPC (HY-113424A), and DSPE-PEG-Maleimide (HY-140740).

Techniques: In Vivo, Ex Vivo, Control, Imaging